PainChek Ltd
ASX:PCK
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
PCK's latest stock split occurred on Nov 28, 2025
The company executed a 1-for-10 stock split, meaning that for every 10 shares held, investors received 1 new share.
Before the split, PCK traded at 0.037 per share. Afterward, the share price was about 0.36.
The adjusted shares began trading on Nov 28, 2025. This was PCK's 5th stock split, following the previous one in Nov 27, 2024.
Global
Stock Splits Monitor
PainChek Ltd
Glance View
PainChek Ltd. engages in the development and commercialisation of mobile medical device applications. The company is headquartered in Sydney, New South Wales. The company went IPO on 2012-05-01. The Company’s principal activities are development and commercialization of mobile medical device applications, that automate intelligent pain assessment of individuals who are unable to communicate their pain with carers. Its Paincheck is an Adult and Infant pain assessment applications. Its PainChek technology uses cameras in smartphones and tablets to capture a brief video of the person, which is analyzed in real time using facial recognition software to detect the presence of facial micro-expressions that are indicative of the presence of pain. Its Paincheck uses artificial intelligence (AI) to automatically assess the micro-facial features of pain. Its PainChek technology has multiple regulatory clearances, including TGA (Australia) and CE Mark (Europe) for use as a class 1 medical device to assess pain in people who are unable to reliably verbalize, such people with dementia.
3902
MMI
002315